JP2017514831A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017514831A5 JP2017514831A5 JP2016565238A JP2016565238A JP2017514831A5 JP 2017514831 A5 JP2017514831 A5 JP 2017514831A5 JP 2016565238 A JP2016565238 A JP 2016565238A JP 2016565238 A JP2016565238 A JP 2016565238A JP 2017514831 A5 JP2017514831 A5 JP 2017514831A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- aluminum
- administered
- immunostimulatory
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 44
- 230000003308 immunostimulating effect Effects 0.000 claims 43
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 claims 30
- FAHBNUUHRFUEAI-UHFFFAOYSA-M hydroxidooxidoaluminium Chemical compound O[Al]=O FAHBNUUHRFUEAI-UHFFFAOYSA-M 0.000 claims 21
- 208000024827 Alzheimer disease Diseases 0.000 claims 16
- 238000002347 injection Methods 0.000 claims 6
- 239000007924 injection Substances 0.000 claims 6
- 239000000725 suspension Substances 0.000 claims 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 3
- 239000007788 liquid Substances 0.000 claims 3
- 239000000126 substance Substances 0.000 claims 3
- -1 Aluminum aluminum salt oxyhydroxide Chemical compound 0.000 claims 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 239000003963 antioxidant agent Substances 0.000 claims 2
- 239000008139 complexing agent Substances 0.000 claims 2
- 229910021645 metal ion Inorganic materials 0.000 claims 2
- 239000002245 particle Substances 0.000 claims 2
- 230000000087 stabilizing effect Effects 0.000 claims 2
- 239000004094 surface-active agent Substances 0.000 claims 2
- 229910018072 Al 2 O 3 Inorganic materials 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims 1
- 229910002651 NO3 Inorganic materials 0.000 claims 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 claims 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 1
- 239000007983 Tris buffer Substances 0.000 claims 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical group [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims 1
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 claims 1
- DIZPMCHEQGEION-UHFFFAOYSA-H aluminium sulfate (anhydrous) Chemical compound [Al+3].[Al+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O DIZPMCHEQGEION-UHFFFAOYSA-H 0.000 claims 1
- 239000000872 buffer Substances 0.000 claims 1
- 239000012928 buffer substance Substances 0.000 claims 1
- 235000014633 carbohydrates Nutrition 0.000 claims 1
- 150000001720 carbohydrates Chemical class 0.000 claims 1
- 239000000835 fiber Substances 0.000 claims 1
- 229910001385 heavy metal Inorganic materials 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 239000008363 phosphate buffer Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 235000000346 sugar Nutrition 0.000 claims 1
- 150000005846 sugar alcohols Chemical class 0.000 claims 1
- 150000008163 sugars Chemical class 0.000 claims 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 claims 1
- 229960004906 thiomersal Drugs 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461985710P | 2014-04-29 | 2014-04-29 | |
| EP14166355.9 | 2014-04-29 | ||
| EP14166355 | 2014-04-29 | ||
| US61/985,710 | 2014-04-29 | ||
| PCT/EP2015/059337 WO2015165964A1 (en) | 2014-04-29 | 2015-04-29 | Treatment and prevention of alzheimer's disease (ad) |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017514831A JP2017514831A (ja) | 2017-06-08 |
| JP2017514831A5 true JP2017514831A5 (https=) | 2018-05-31 |
Family
ID=50555097
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016565238A Pending JP2017514831A (ja) | 2014-04-29 | 2015-04-29 | アルツハイマー病（ａｄ）の処置および予防 |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US10646565B2 (https=) |
| EP (1) | EP3137097B1 (https=) |
| JP (1) | JP2017514831A (https=) |
| KR (1) | KR102460465B1 (https=) |
| CN (1) | CN106535924A (https=) |
| AU (3) | AU2015254661A1 (https=) |
| CA (1) | CA2946929A1 (https=) |
| ES (1) | ES2953381T3 (https=) |
| PL (1) | PL3137097T3 (https=) |
| WO (2) | WO2015165964A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3137094T3 (pl) * | 2014-04-29 | 2023-03-13 | Advantage Therapeutics, Inc. | Leczenie i profilaktyka choroby alzheimera (ad) |
| EP3137097B1 (en) | 2014-04-29 | 2023-06-21 | ADvantage Therapeutics, Inc. | Treatment and prevention of alzheimer's disease (ad) |
| EP3137093B1 (en) * | 2014-04-29 | 2017-09-13 | Affiris AG | Treatment and prevention of alzheimer's disease (ad) |
| EP3643319A1 (en) * | 2018-10-25 | 2020-04-29 | Grifols Worldwide Operations Limited | Use of low volume plasma exchange for the treatment of alzheimer's disease in early and middle stages |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994016327A1 (en) * | 1993-01-14 | 1994-07-21 | Pollard Harvey B | Methods and compositions for blocking amyloid protein ion channels |
| TWI239847B (en) * | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
| US6905686B1 (en) * | 1997-12-02 | 2005-06-14 | Neuralab Limited | Active immunization for treatment of alzheimer's disease |
| US7964192B1 (en) * | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
| AT413946B (de) * | 2004-07-13 | 2006-07-15 | Mattner Frank Dr | Impfstoff gegen die alzheimer-krankheit |
| WO2009105641A2 (en) * | 2008-02-20 | 2009-08-27 | New York University | Preventing and treating amyloid-beta deposition by stimulation of innate immunity |
| AT506820B1 (de) * | 2008-06-12 | 2011-07-15 | Affiris Forschungs Und Entwicklungs Gmbh | Vakzine gegen alzheimer-krankheit |
| AT506819B1 (de) * | 2008-06-12 | 2011-06-15 | Affiris Forschungs Und Entwicklungs Gmbh | Vakzin zur behandlung von alzheimer-krankheit |
| BR112012024708A2 (pt) * | 2010-03-29 | 2016-06-07 | Novartis Ag | composição de compostos orgânicos |
| EP2659908A1 (en) * | 2012-05-01 | 2013-11-06 | Affiris AG | Compositions |
| EP3137097B1 (en) | 2014-04-29 | 2023-06-21 | ADvantage Therapeutics, Inc. | Treatment and prevention of alzheimer's disease (ad) |
| PL3137094T3 (pl) * | 2014-04-29 | 2023-03-13 | Advantage Therapeutics, Inc. | Leczenie i profilaktyka choroby alzheimera (ad) |
| EP3137093B1 (en) * | 2014-04-29 | 2017-09-13 | Affiris AG | Treatment and prevention of alzheimer's disease (ad) |
-
2015
- 2015-04-29 EP EP15720058.5A patent/EP3137097B1/en active Active
- 2015-04-29 PL PL15720058.5T patent/PL3137097T3/pl unknown
- 2015-04-29 US US15/307,714 patent/US10646565B2/en active Active
- 2015-04-29 AU AU2015254661A patent/AU2015254661A1/en not_active Abandoned
- 2015-04-29 WO PCT/EP2015/059337 patent/WO2015165964A1/en not_active Ceased
- 2015-04-29 CA CA2946929A patent/CA2946929A1/en not_active Abandoned
- 2015-04-29 KR KR1020167033323A patent/KR102460465B1/ko active Active
- 2015-04-29 ES ES15720058T patent/ES2953381T3/es active Active
- 2015-04-29 CN CN201580029876.1A patent/CN106535924A/zh active Pending
- 2015-04-29 WO PCT/EP2015/059355 patent/WO2015165974A1/en not_active Ceased
- 2015-04-29 JP JP2016565238A patent/JP2017514831A/ja active Pending
-
2020
- 2020-03-17 US US16/821,557 patent/US11147873B2/en active Active
-
2021
- 2021-01-08 AU AU2021200093A patent/AU2021200093B2/en active Active
- 2021-09-23 US US17/482,579 patent/US20220062412A1/en active Pending
-
2024
- 2024-02-20 AU AU2024201099A patent/AU2024201099A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017514831A5 (https=) | ||
| US20120070417A1 (en) | Anti-influenza formulations and methods | |
| JP2019528320A5 (https=) | ||
| JP2015519404A5 (https=) | ||
| RU2010150839A (ru) | Внутрилегочное введения флуорохинолона | |
| JP2015527402A5 (https=) | ||
| EP4108253A1 (en) | Rapid-acting insulin compositions | |
| JP2018523635A (ja) | 抗ウイルス活性を有する鼻づまり解除組成物 | |
| JP2013513612A5 (https=) | ||
| RU2016119746A (ru) | Стабильный состав инсулина глулизин | |
| TAKACS et al. | Amphotericin B nephrotoxicity with irreversible renal failure | |
| IL291556B2 (en) | Methods and compositions for administration of arylsulfatase A to the central nervous system | |
| RU2012102247A (ru) | Инъекционные композиции, содержащие асенапин и способ лечения с их применением | |
| CN104203232A (zh) | 用于抗肿瘤试剂施用的方法 | |
| BR112012003907A2 (pt) | composições farmacêuticas para prevenção ou tratamento da osteoporose, a ser adminstrada uma vez por mês | |
| CN109512802A (zh) | 一种退热贴及其制备方法 | |
| JP2002500169A (ja) | テオレル−マイヤー勾配に基づく薬投与形 | |
| KR102392454B1 (ko) | 방사성 핵종 및 금속의 킬레이트제를 전달하기 위한 역-미셀계의 이용 | |
| CN103070881B (zh) | 一种阴道抑菌、杀病毒组合物及其应用 | |
| CN113226251B (zh) | 高负载分散体的混悬剂制剂 | |
| JPH02196716A (ja) | 薬学的溶液 | |
| JP2017515812A5 (https=) | ||
| CN103203032B (zh) | 锝[99Tc]亚甲基二膦酸盐制剂及其制备方法 | |
| WO2011149844A1 (en) | Delivery of high dose therapeutic radioisotopes to bone | |
| CN102670690A (zh) | 一种抗牛皮癣纯天然药物乳膏及其制备方法 |